Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062329) 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062329 International Application No.: PCT/CN2018/098481
Publication Date: 04.04.2019 International Filing Date: 03.08.2018
IPC:
C07D 471/04 (2006.01) ,C07D 487/04 (2006.01) ,A61K 31/437 (2006.01) ,A61K 31/519 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
上海海雁医药科技有限公司 SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. [CN/CN]; 中国上海市 浦东新区张江高科技园区李冰路67弄8号 No. 8 Lane 67, Libing Road, Zhangjiang High-Tech Park, Pudong New Area Shanghai 201203, CN
扬子江药业集团有限公司 YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. [CN/CN]; 中国江苏省泰州市 高港区扬子江南路1号 No. 1 South Yangtze River Road, Gaogang District Taizhou, Jiangsu 225321, CN
Inventors:
郭淑春 GUO, Shuchun; CN
周福生 ZHOU, Fusheng; CN
陈祥 CHEN, Xiang; CN
赵金柱 ZHAO, Jinzhu; CN
黄栋 HUANG, Dong; CN
谢婧 XIE, Jing; CN
乔长江 QIAO, Changjiang; CN
何宛 HE, Wan; CN
张凯 ZHANG, Kai; CN
陈曦 CHEN, Xi; CN
兰炯 LAN, Jiong; CN
Agent:
上海智晟知识产权代理事务所(特殊普通合伙) ZHISHENG IP, LLP.; 中国上海市 徐汇区钦州北路1089号51号楼501室 Room 501 No. 51 Building, No. 1089 North QinZhou RD, Xuhui District Shanghai 200233, CN
Priority Data:
201710897909.528.09.2017CN
Title (EN) 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE
(FR) DÉRIVÉ 4,6,7-TRISUBSTITUÉ DE 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE ET SON UTILISATION
(ZH) 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
Abstract:
(EN) Provided are a 4,6,7-trisubstituted 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof and a preparation method and application of the same. The definition of each substituent in the formula is described in detail in the specification and claims.
(FR) L'invention concerne un dérivé 4,6,7-trisubstitué de 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one, et son procédé de préparation et son utilisation pharmaceutique. En particulier, la présente invention concerne un composé de formule (I) ou un stéréoisomère, un solvate, un promédicament ou un sel pharmaceutiquement acceptable de celui-ci, et un procédé de préparation et une application de celui-ci. La définition de chaque substituant dans la formule est décrite en détail dans la description et les revendications.
(ZH) 提供一种4,6,7-三取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物、其制法与医药上的用途。具体地,涉及一种式(I)化合物或其药学上可接受的盐、立体异构体、溶剂化物或前药,及其制备方法和应用,式中各基团的定义详见说明书和权利要求书。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)